NUVB Stock Forecast: Nuvation Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Nuvation Bio, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 63 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Nuvation Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NUVB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NUVB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $21 |
| 5 Nov 2026 | RBC Capital | Maintains | Outperform | $20 → $17 |
| 30 Sept 2026 | Citigroup | Initiates | Buy | $12 |
| 16 Sept 2026 | Citizens | Reiterates | Market Outperform | $10 |
| 16 Sept 2026 | Wedbush | Reiterates | Outperform | $11 |
| 21 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Aug 2026 | JP Morgan | Initiates | Overweight | $13 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $19 → $20 |
| 27 July 2026 | HC Wainwright & Co. | Maintains | Buy | $17 → $21 |
| 23 July 2026 | Wedbush | Reiterates | Outperform | $11 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $20 → $19 |
| 7 July 2026 | Truist Securities | Maintains | Buy | $12 → $13 |
| 5 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | RBC Capital | Reiterates | Outperform | — |
| 5 May 2026 | Wedbush | Reiterates | Outperform | — |
| 16 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 2 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 27 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 3 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 3 Mar 2026 | UBS | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NUVB.
This page is one stock. Monday covers all of them.
NUVB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NUVB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Nuvation Bio, Inc. returned −45.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NUVB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6.6×
- Price / book
- 5.9×
- EV / EBITDA
- —
Cheaper than 16% of US stocks
Cheaper than 15% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 70.1%
- Operating margin
- −61.2%
- Net margin
- —
Higher than 83% of US stocks
Higher than 17% of US stocks
- Return on equity
- −49.1%
- Return on assets
- −11.2%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nuvation Bio, Inc. has a market value of $1.3B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $169.9M. The latest quarter grew 555.6% year on year.
Net income over the same four quarters: −$149.8M, a −88.2% net margin.
Diluted earnings per share, trailing twelve months: −$0.44.
Free cash flow in the twelve months to 30 June 2026: −$128.9M.
Nuvation Bio, Inc. employs 310 people — $548K of revenue per employee.
Data provided by Twelve Data
NUVB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NUVB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Nuvation Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NUVB
What is the NUVB stock price forecast for 2026-2027?
The median 12-month analyst price target for Nuvation Bio, Inc. is $12, with estimates ranging from $7 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NUVB stock a buy right now?
Of the 13 analysts covering Nuvation Bio, Inc., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvation Bio, Inc. 63 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NUVB?
As at 21 Nov 2026, Nuvation Bio, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
Will NUVB stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts is $12, and Ticker Nerd's factor model ranks Nuvation Bio, Inc. 63 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NUVB stock forecast for 2030?
No analyst covering Nuvation Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUVB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $21 over the next 12 months.
How has NUVB stock performed over the past year?
Nuvation Bio, Inc. returned -45.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Nuvation Bio, Inc. do?
Nuvation Bio Inc. Class A Common Stock represents ownership in Nuvation Bio, a global oncology company focused on developing differentiated therapeutic candidates for difficult-to-treat cancers. The company’s current work centers on advancing a portfolio of oncology programs that includes targeted therapies, brain-penetrant inhibitors, and drug-drug conjugate candidates designed to address unmet needs across several cancer types.
About Nuvation Bio, Inc.
Nuvation Bio Inc. Class A Common Stock represents ownership in Nuvation Bio, a global oncology company focused on developing differentiated therapeutic candidates for difficult-to-treat cancers. The company’s current work centers on advancing a portfolio of oncology programs that includes targeted therapies, brain-penetrant inhibitors, and drug-drug conjugate candidates designed to address unmet needs across several cancer types. Its pipeline spans areas such as non-small cell lung cancer, gliomas, and other solid tumors, reflecting a research and development model built around precision medicine and novel mechanisms of action. Nuvation Bio operates as a biopharmaceutical business within the healthcare sector, where it contributes to the broader oncology market through clinical-stage drug development and scientific innovation.
CEO Dr. David T. Hung M.D. · 310 employees · United States · https://www.nuvationbio.com